How pharmacists can lead the change as the FDA fast-tracks biosimilars.
Biologic medicines like monoclonal antibodies, fusion proteins, and insulin analogues have shaped the landscape of specialty pharmacy. For years, biosimilars opened doors to lower cost options. But in 2025, interchangeable biosimilars have taken center stage, quietly overturning old rules and rewriting what’s possible for access, affordability, and the pharmacist’s role (Biosimilars Council, 2024; U.S. FDA, 2025).
Why Interchangeable Biologics Matter More Than Ever
Not every biosimilar is created equal. When the FDA grants the interchangeable designation, it means a pharmacist can substitute the biosimilar for its reference product (like Humira or Stelara) at the pharmacy counter without calling the prescriber (U.S. FDA, 2024). That’s a seismic shift; it’s about making access easier, costs lower, and putting more clinical decision making in our hands (Ling et al., 2025).
The Latest Wave: New Approvals, New Possibilities
The first half of 2025 has been a blur of progress:
- Yuflyma (adalimumab-aaty): In May, this Humira biosimilar became fully interchangeable across every dosage form (BiologicsHQ, 2025).
- Hadlima (adalimumab-bwwd): Also in May, this product joined the ranks as a full-spectrum Humira equivalent (IPD Analytics, 2025).
- Stelara biosimilars: Selarsdi (ustekinumab-aekn), Otulfi (ustekinumab-aauz), and Starjemza (ustekinumab-hmny) all won interchangeable status this spring, expanding options in immunology (The Rheumatologist, 2025).
Behind these approvals is a regulatory sea change. In June 2024, the FDA dropped the requirement for clinical switching studies, clearing the path for faster, more affordable biosimilar development (U.S. FDA, 2024; IPD Analytics, 2024). At a September 2025 public workshop, the FDA hinted at further simplification ahead (U.S. FDA, 2025).
What Does This Mean for Pharmacists?
Retail Pharmacy: Substitution, Savings, and State Laws
You can now substitute certain biologics at the point of sale, but the rules vary by state (Avalere Health, 2025). Some require prescriber notification; others mandate patient consent or extra documentation. Knowing your state law is non-negotiable.
Patient conversations matter. “This product meets the FDA’s interchangeable standard and can be substituted, depending on state law” is a phrase we’ll use often (APhA, 2024). Patients will have questions about safety, effectiveness, cost, and insurance, and pharmacists are best positioned to answer them.
Specialty Pharmacy: Managing Transitions and Maximizing Value
Formulary negotiations and payer policies are about to get more complex. Expect insurers to shift toward preferred biosimilars, tiered pricing, and even mandated substitutions (Pharmacist.com, 2024).
Patient counseling takes on new urgency. Switching between infusion and subcutaneous products (or among biologics) means tracking side effects, immunogenicity, and outcomes. Documentation and tracking are essential for safety, reimbursement, and building trust with both providers and patients (Ling et al., 2025).
Insurance, Cost, and Access
Savings are real. Analysts predict billions in U.S. healthcare savings as interchangeable biosimilars crowd the market and payers push adoption (Biosimilars Council, 2024).
But navigation remains tricky. Preferred tiers, copay structures, and prior authorizations can still derail access. Pharmacists play a vital role in ensuring patients find the most affordable and clinically sound option, and that no one is surprised at the pharmacy counter (Avalere Health, 2025).
What’s on the Horizon?
Regulation is a moving target. The FDA’s September 2025 workshop and new draft strategies suggest even more streamlined pathways ahead (U.S. FDA, 2025). The pipeline is booming. Expect a surge of interchangeable biosimilars in immunology, oncology, and endocrinology through 2028 (IPD Analytics, 2025).
As volume grows, so will the pharmacist’s responsibility to negotiate, educate, and design safe, efficient protocols centered on patient care.
More Than Substitution: An Expanded Role for Pharmacy
Interchangeable biosimilars aren’t just another option, they’re an opportunity for pharmacists to lead. Our expertise, communication, and systems thinking will determine how smoothly this transition unfolds.
Ask yourself:
- Do I know my state’s substitution laws?
- Is my team ready to counsel on new biosimilar options?
- Are we tracking outcomes and continuity during switches?
- Am I proactive about payer policies and advocating for access?
This is our moment to move from gatekeeper to architect. Let’s make it count.
American Pharmacists Association. (2024). Interchangeable biosimilars: Focus on interchangeable biosimilars. https://www.pharmacist.com/Advocacy/Issues/Biosimilars
Avalere Health. (2025, July 1). 2025 Update: Biosimilar substitution state statute report. https://www.avalere.com/insights/new-resource-biosimilar-substitution-state-statute-report
BiologicsHQ. (2025, May 12). May 2025 Stelara and Humira interchangeable biosimilar approvals. https://www.biologicshq.com/may-2025-stelara-and-humira-interchangeable-biosimilar-approvals
Biosimilars Council. (2024). Focus on interchangeable biosimilars. Washington, DC.
IPD Analytics. (2024, August 16). FDA proposes dropping switching-study requirement for biosimilars. https://www.ipdanalytics.com/post/biosimilar-interchangeability-fda-designation-marketing-exclusivity-guidance-and-future-trends
IPD Analytics. (2025, July 17). Biosimilars boom: 2025’s fast-track approvals look to reshape healthcare. https://www.ipdanalytics.com/post/biosimilars-boom-2025s-fast-track-approvals-look-to-reshape-healthcare/
Ling, Y. L., et al. (2025). Real-world familiarity with U.S. biosimilar regulatory environment and impact on pharmacist recommendation practices. Journal of Managed Care & Specialty Pharmacy, 31(6), 552–560. https://doi.org/10.18553/jmcp.2025.31.6.552
Pharmacist.com. (2024). Biosimilars: What benefits do biosimilars offer? https://www.pharmacist.com/Advocacy/Issues/Biosimilars
The Rheumatologist. (2025, February 14). Yuflyma and Hadlima gain interchangeable status in 2025. https://www.the-rheumatologist.org/article/yuflyma-and-hadlima-gain-interchangeable-status-in-2025/
U.S. Food and Drug Administration. (2024, June 20). FDA updates guidance on interchangeability. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-guidance-interchangeability
U.S. Food and Drug Administration. (2025, September 19). Public workshop: Future needs for the development of interchangeable products. https://www.fda.gov/industry/fda-public-workshop-future-needs-development-interchangeable-products-09192025
